JP2016505010A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505010A5
JP2016505010A5 JP2015552726A JP2015552726A JP2016505010A5 JP 2016505010 A5 JP2016505010 A5 JP 2016505010A5 JP 2015552726 A JP2015552726 A JP 2015552726A JP 2015552726 A JP2015552726 A JP 2015552726A JP 2016505010 A5 JP2016505010 A5 JP 2016505010A5
Authority
JP
Japan
Prior art keywords
compound
dihydro
formula
pharmaceutically acceptable
salt according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015552726A
Other languages
English (en)
Japanese (ja)
Other versions
JP6285461B2 (ja
JP2016505010A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/010400 external-priority patent/WO2014110000A1/en
Publication of JP2016505010A publication Critical patent/JP2016505010A/ja
Publication of JP2016505010A5 publication Critical patent/JP2016505010A5/ja
Application granted granted Critical
Publication of JP6285461B2 publication Critical patent/JP6285461B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015552726A 2013-01-11 2014-01-07 二環式ピリミジン化合物 Expired - Fee Related JP6285461B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361751363P 2013-01-11 2013-01-11
US61/751,363 2013-01-11
US201361777201P 2013-03-12 2013-03-12
US61/777,201 2013-03-12
PCT/US2014/010400 WO2014110000A1 (en) 2013-01-11 2014-01-07 Pyrido- or pyrrolo-fused pyrimidine derivatives as autotaxin inhibitors for treating pain

Publications (3)

Publication Number Publication Date
JP2016505010A JP2016505010A (ja) 2016-02-18
JP2016505010A5 true JP2016505010A5 (OSRAM) 2017-02-16
JP6285461B2 JP6285461B2 (ja) 2018-02-28

Family

ID=50031555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552726A Expired - Fee Related JP6285461B2 (ja) 2013-01-11 2014-01-07 二環式ピリミジン化合物

Country Status (13)

Country Link
US (1) US8969555B2 (OSRAM)
EP (1) EP2943494B1 (OSRAM)
JP (1) JP6285461B2 (OSRAM)
KR (1) KR101757997B1 (OSRAM)
CN (1) CN104903327B (OSRAM)
AU (1) AU2014205642B2 (OSRAM)
BR (1) BR112015015812A2 (OSRAM)
CA (1) CA2893253C (OSRAM)
EA (1) EA025106B1 (OSRAM)
ES (1) ES2636248T3 (OSRAM)
MX (1) MX2015008971A (OSRAM)
TW (1) TWI499591B (OSRAM)
WO (1) WO2014110000A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201500356A (zh) * 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物
WO2015077503A1 (en) 2013-11-22 2015-05-28 Pharmakea, Inc. Autotaxin inhibitor compounds
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
AU2016268250B2 (en) 2015-05-27 2020-08-27 Sabre Therapeutics Llc Autotaxin inhibitors and uses thereof
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
US10961242B2 (en) 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
EP3805234B1 (en) * 2018-05-24 2024-09-04 Guangzhou Henovcom Bioscience Co., Ltd. Aromatic heterocyclic compound, and pharmaceutical composition and use thereof
CA3106641A1 (en) * 2018-07-16 2020-01-23 The Scripps Research Institute Opioid haptens, conjugates, vaccines, and methods of generating antibodies
CN111518101B (zh) * 2019-02-01 2022-07-29 武汉人福创新药物研发中心有限公司 吡咯并嘧啶衍生物及其用途
CA3149062A1 (en) * 2019-09-06 2021-03-11 Xuejun Zhang Pyrimidine compound and preparation method therefor
WO2021055612A1 (en) * 2019-09-17 2021-03-25 BIAL-BioTech Investments, Inc. Substituted imidazole carboxamides and their use in the treatment of medical disorders
WO2021088957A1 (zh) * 2019-11-07 2021-05-14 广州市恒诺康医药科技有限公司 芳杂环化合物、其药物组合物及其应用
AU2020402940A1 (en) * 2019-12-11 2022-06-02 Sichuan Haisco Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic autotaxin inhibitor, and composition containing same and use thereof
CN113943296B (zh) * 2020-07-16 2025-07-04 武汉人福创新药物研发中心有限公司 吡咯并嘧啶衍生物及其应用
CN113943295B (zh) * 2020-07-16 2025-08-12 武汉人福创新药物研发中心有限公司 吡咯并嘧啶类化合物及其用途
CN113999236B (zh) * 2020-07-28 2025-06-10 武汉人福创新药物研发中心有限公司 含氮杂环化合物的盐及其盐的固体形式、药物组合物和用途
WO2022022569A1 (zh) * 2020-07-28 2022-02-03 武汉人福创新药物研发中心有限公司 含氮杂环化合物的固体形式及其药物组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1071301A (en) * 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
WO2003104230A1 (ja) 2002-06-07 2003-12-18 協和醱酵工業株式会社 二環性ピリミジン誘導体
DE102004020908A1 (de) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
WO2006119504A2 (en) * 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
SG171809A1 (en) * 2008-12-01 2011-07-28 Merck Patent Gmbh 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer
WO2012009258A2 (en) * 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
JP2013536200A (ja) 2010-08-20 2013-09-19 アミラ ファーマシューティカルス,インコーポレーテッド オートタキシン阻害剤およびその使用
AR084515A1 (es) * 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
WO2013054185A1 (en) * 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
EP2771325B1 (en) * 2011-10-28 2017-06-28 Inhibitaxin Limited Pyridazine derivatives useful in therapy
TW201520219A (zh) * 2013-03-12 2015-06-01 Lilly Co Eli 咪唑並吡啶化合物
TW201500356A (zh) * 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物

Similar Documents

Publication Publication Date Title
JP2016505010A5 (OSRAM)
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
JP2016523270A5 (OSRAM)
JP2014513139A5 (OSRAM)
JP2010523522A5 (OSRAM)
CN113767106A (zh) 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途
JP2016523974A5 (OSRAM)
JP2017509689A5 (OSRAM)
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
JP2019523214A5 (OSRAM)
JP2016530283A5 (OSRAM)
JP2017509586A5 (OSRAM)
JP2015514808A5 (OSRAM)
JP2019524883A5 (OSRAM)
WO2016096174A8 (en) Cyclic dinucleotides for cytokine induction
JP2013512953A5 (OSRAM)
JP2018513150A5 (OSRAM)
JP2015506348A5 (OSRAM)
JP2014521625A5 (OSRAM)
JP2017501236A5 (OSRAM)
JP2017504635A5 (OSRAM)
JP2016520618A5 (OSRAM)
JP2013523802A5 (OSRAM)
JP2016540803A5 (OSRAM)
ME02838B (me) 3,4-dihidroizokinolin-2(1h)-ilni spojevi